Sign in
4

Changes in Ownership

Denali Therapeutics Inc. Filed Acc 0001714899-23-000029

President and CEO sold 33,815 shares at an average $30.08 ($1,017,243)

  • President and CEO acquired 25,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Watts Ryan J. · President and CEO

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2023-02-13 Sale : show line 1 in the form −8,815 $30.09 $265,243 2,239,913 I
2023-02-13 Exercise or conversion : show line 2 in the form +25,000 $0.68 $17,000 2,264,913 I
2023-02-13 Sale : show line 3 in the form −25,000 $30.08 $752,000 2,239,913 I
Open-market sales · 33,815 sh · avg $30.08 · $1,017,243

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2023-02-13 Exercise or conversion : show line 4 in the form Stock Option (right to buy) −25,000 1,195,617 D
Loading xslF345X03/wf-form4_167650567156375.xml…